Kristina Meyer

Summary

With over 20 years of international business development experience in the life sciences industry, I am a driven, self-motivated, and creative professional who creats win-win solutions for all stakeholders. I have a deep understanding of a large variety of deal types, including in- and out-licensing (with and without equity component), co-development, cross-licensing, discovery collaborations, and fee-for-service models. I am experienced in commercial assessments, valuations, forecasting, and market access & pricing, go-to-market strategy. As the EVP of Business Development at Inventiva Pharma, a clinical-stage biotech company focused on fibrosis, metabolic and rare diseases, and oncology, I led all in- and out-licensing activities for the company. I was responsible for the pre-commercial strategy for Inventiva's lead asset, lanifibranor, a pan-PPAR agonist, currently in phase III development in metabolic-associated steatohepatitis MASH. I have recently secured transactions with international pharmaceutical companies, such as partnerships for Inventiva's phase III NASH/MASH asset with Sino Biopharm in Greater China and Hepalys in Japan and Korea. I also supported corporate financing activities, led the Alliance Management fuction and served as the liaison for rare disease patient associations and patients. I have a Ph.D. in Chemistry from J.W. Goethe University and a postdoc in Molecular Biology and Biophysics from Yale University. I am fluent in English and German.